Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S
November 02 2023 - 10:14AM
Resolutions of the Extraordinary General Meeting of Pharma Equity
Group A/S
2 November 2023
Announcement no. 43
Resolutions of the Extraordinary General
Meeting of Pharma Equity Group A/S
Pharma Equity Group A/S today held its
Extraordinary General Meeting with the following results:
1) Attorney Martin Allan
Christensen from Accura Advokatpartnerselskab was elected as
chairman at the extraordinary general meeting.
2) The following new
candidates were elected to the Board of Directors: (i) Omar S.
Qandeel, and (ii) Martin Engell-Rossen.
The Board of Director immediately thereafter
constituted itself with Christian Vinding Thomsen as the Chairman
of the Board of Directors and Martin Engell-Rossen as the Vice
Chairman of the Board of Directors.
The Board of Directors will thereafter consist
of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice
Chairman), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.
For further information, please
contact:
Thomas Kaas Selsø, CEO of Pharma Equity Group
A/S, phone: +45 40 22 21 14
Christian Vinding Thomsen, Chairman of the Board
of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring
the utmost success and impact of Reponex Pharmaceuticals'
medical projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open
to new strategic investments for continuous growth.
- 2023 11 02 - Announcement no. 43 - UK
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jul 2023 to Jul 2024